{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:53:59Z","timestamp":1782982439616,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2025.106043","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:17:56Z","timestamp":1770916676000},"page":"106043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-4082","authenticated-orcid":false,"given":"T.","family":"Macarulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-7391","authenticated-orcid":false,"given":"R.Pazo","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Womack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cubillo","family":"Gracian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zervoudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hatoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"E.M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-2870","authenticated-orcid":false,"given":"F.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.106043_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.106043_bib3","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2147\/OTT.S232464","article-title":"Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106043_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MPA.0000000000000091","article-title":"Pancreatic cancer survival in elderly patients treated with chemotherapy","volume":"43","author":"Sehgal","year":"2014","journal-title":"Pancreas"},{"issue":"12","key":"10.1016\/j.esmoop.2025.106043_bib5","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/cam4.1240","article-title":"Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer","volume":"6","author":"van der Geest","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2025.106043_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102215","article-title":"Are older patients less likely to be treated for pancreatic cancer? A systematic review and meta-analysis","volume":"80","author":"Logan","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.106043_bib7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2025.106043_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.106043_bib9","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106043_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1756283X17713879","article-title":"Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions","volume":"10","author":"Lambert","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106043_bib11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s12094-024-03386-8","article-title":"Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology","volume":"26","author":"Guillot Morales","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2025.106043_bib12","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2024.42.16_suppl.4003","article-title":"A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na\u00efve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186","volume":"42","author":"Dotan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106043_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgo.2018.11.001","article-title":"Advanced pancreatic cancer clinical trials: the continued underrepresentation of older patients","volume":"10","author":"White","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"10409","key":"10.1016\/j.esmoop.2025.106043_bib16","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106043_bib17","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.106043_bib18","article-title":"DNA damage with liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts: multimodal analysis of deposition characteristics","volume":"36","author":"Klinz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106043_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105534","article-title":"Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial","volume":"10","author":"Melisi","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106043_bib21","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2025.106043_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231175441","article-title":"Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis","volume":"15","author":"Jung","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106043_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pan.2016.12.009","article-title":"Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis","volume":"17","author":"Baldini","year":"2017","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106043_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jgo.2018.03.007","article-title":"An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma","volume":"9","author":"Castel-Kremer","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106043_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jgo.2017.08.007","article-title":"How to treat pancreatic adenocarcinoma in elderly: how far can we go in 2017?","volume":"8","author":"Gilabert","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.106043_bib26","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106043_bib27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106043_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/reports8020069","article-title":"An 81-year-old geriatric patient with metastatic pancreatic cancer demonstrating excellent response and well tolerance to NALIRIFOX: a case report and literature review","volume":"8","author":"Khasawneh","year":"2025","journal-title":"Reports (MDPI)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:11:41Z","timestamp":1777623101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925019131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702925019131"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106043","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106043"}}